Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide versus placebo in NASH with compensated cirrhosis (fibrosis stage 4)
2018-004484-31Phase 2Unknown
- Sponsor
- Novo Nordisk
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis comparing Semaglutide 2.4 mg once-weekly with Placebo once-weekly (2 arms). Primary endpoint: Relative change in liver stiffness measured by MRE. Status: unknown.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on 2018-004484-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004484-31.